These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 24434211)

  • 1. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.
    Peltonen K; Colis L; Liu H; Trivedi R; Moubarek MS; Moore HM; Bai B; Rudek MA; Bieberich CJ; Laiho M
    Cancer Cell; 2014 Jan; 25(1):77-90. PubMed ID: 24434211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress.
    Peltonen K; Colis L; Liu H; Jäämaa S; Zhang Z; Af Hällström T; Moore HM; Sirajuddin P; Laiho M
    Mol Cancer Ther; 2014 Nov; 13(11):2537-46. PubMed ID: 25277384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors.
    Colis L; Ernst G; Sanders S; Liu H; Sirajuddin P; Peltonen K; DePasquale M; Barrow JC; Laiho M
    J Med Chem; 2014 Jun; 57(11):4950-61. PubMed ID: 24847734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
    Low JY; Sirajuddin P; Moubarek M; Agarwal S; Rege A; Guner G; Liu H; Yang Z; De Marzo AM; Bieberich C; Laiho M
    Prostate; 2019 Dec; 79(16):1837-1851. PubMed ID: 31524299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RNA polymerase I transcription machinery in cancer cells by a novel monofunctional platinum-based agent.
    Zhang ZL; Zhao CL; Chen Q; Xu K; Qiao X; Xu JY
    Eur J Med Chem; 2018 Jul; 155():434-444. PubMed ID: 29908438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ribosomal G-quadruplexes with naphthalene-diimides as RNA polymerase I inhibitors for colorectal cancer treatment.
    Sanchez-Martin V; Schneider DA; Ortiz-Gonzalez M; Soriano-Lerma A; Linde-Rodriguez A; Perez-Carrasco V; Gutierrez-Fernandez J; Cuadros M; González C; Soriano M; Garcia-Salcedo JA
    Cell Chem Biol; 2021 Nov; 28(11):1590-1601.e4. PubMed ID: 34166611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of RNA polymerase I catalytic core is influenced by RPA12.
    Ford BL; Wei T; Liu H; Scull CE; Najmi SM; Pitts S; Fan W; Schneider DA; Laiho M
    PLoS One; 2023; 18(5):e0285660. PubMed ID: 37167337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.
    Santamaría Nuñez G; Robles CM; Giraudon C; Martínez-Leal JF; Compe E; Coin F; Aviles P; Galmarini CM; Egly JM
    Mol Cancer Ther; 2016 Oct; 15(10):2399-2412. PubMed ID: 27630271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint.
    Wei T; Najmi SM; Liu H; Peltonen K; Kucerova A; Schneider DA; Laiho M
    Cell Rep; 2018 Apr; 23(2):404-414. PubMed ID: 29642000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small-molecule BMH-21 directly inhibits transcription elongation and DNA occupancy of RNA polymerase I in vivo and in vitro.
    Jacobs RQ; Huffines AK; Laiho M; Schneider DA
    J Biol Chem; 2022 Jan; 298(1):101450. PubMed ID: 34838819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
    Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer.
    Wang Z; Wang D; Han S; Wang N; Mo F; Loo TY; Shen J; Huang H; Chen J
    PLoS One; 2013; 8(2):e56631. PubMed ID: 23457597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.
    Jaiswal AS; Banerjee S; Panda H; Bulkin CD; Izumi T; Sarkar FH; Ostrov DA; Narayan S
    Mol Cancer Res; 2009 Dec; 7(12):1973-83. PubMed ID: 19996303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting RNA Polymerase I with Hernandonine Inhibits Ribosomal RNA Synthesis and Tumor Cell Growth.
    Chen YT; Chen JJ; Wang HT
    Mol Cancer Res; 2019 Nov; 17(11):2294-2305. PubMed ID: 31409627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.